Centers for Disease Control and Prevention Advisory Committee on Immunization Practice Records of the Meeting Held On

By Department of Health and Human Services

Book Id: WPLBN0000002050
Format Type: PDF eBook
File Size: 0.4 MB
Reproduction Date: 2005

Title:	Centers for Disease Control and Prevention Advisory Committee on Immunization Practice Records of the Meeting Held On
Author:	Department of Health and Human Services
Volume:
Language:	English
Subject:	Health., Medical research, Medical reports
Collections:	Medical Library Collection
Historic Publication Date:
Publisher:	Centers for Disease Control and Prevention


Citation APA MLA Chicago Health And Human Services, D. O. (n.d.). Centers for Disease Control and Prevention Advisory Committee on Immunization Practice Records of the Meeting Held On. Retrieved from http://www.gutenberg.cc/

Excerpt
OPENING COMMENTS/DISCLOSURES: Chairman Dr. John Modlin convened the meeting at 8: 36 a.m., and introduced Dr. Dixie Snider, the ACIP Executive Secretary. Announcing liaison representatives changes, Dr. Snider welcomed Dr. Gary Overturf of the University of New Mexico Medical Center, as the liaison for the American Academy of Pediatrics; and Mr. Kevin Reilly, President of Wyeth Vaccines and Nutrition, liaison for the Pharmaceutical Research and Manufacturers of America. He announced that Dr. Larry Pickering had joined the National Immunization Program staff. Dr. David Salisbury will serve as the Ex-Officio representative from the London Department of Health and Dr. David Wilson will serve for the American Medical Association, but neither were present at this meeting.

Table of Contents
TABLE OF CONTENTS Meeting Attendance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1/3 MINUTES OF THE MEETING JUNE 20, 2001 OPENING COMMENTS/DISCLOSURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 UPDATE: TETANUS TOXOID VACCINE SHORTAGE/DTaP SUPPLY . . . . . . . . 2 INFLUENZA VACCINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 HEPATITIS B IMMUNIZATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 VACCINE SAFETY ISSUES FOR YELLOW FEVER VACCINE . . . . . . . . . . . . . 19 VACCINE SAFETY UPDATES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 The Brighton Collaboration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 IOM Immunization Safety Review Committee . . . . . . . . . . . . . . . . . . . . . . . . . 24 Update on Thimerosal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 PUBLIC COMMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 JUNE 22, 2001 UNFINISHED BUSINESS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Review of the Edited Influenza Supplementary Statement . . . . . . . . . . . . . . . 31 AGENCY UPDATES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 National Immunization Program (NIP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Food and Drug Administration (FDA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 National Vaccine Injury Compensation Program (NVICP) . . . . . . . . . . . . . . . 34 National Vaccine Program Office (NVPO) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 National Center for Infectious Diseases (NCID) . . . . . . . . . . . . . . . . . . . . . . . . 37 GENERAL RECOMMENDATIONS ON IMMUNIZATION . . . . . . . . . . . . . . . . . . 37 UPDATE: DISCONTINUATION OF HUMAN RABIES VACCINE FOR INTRADERMAL PRE-EXPOSURE USE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 UPDATE ON DEVELOPMENT OF HIV VACCINE . . . . . . . . . . . . . . . . . . . . . . . . 43 HARMONIZED SCHEDULE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Adult Harmonized Schedule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 LABORATORY-ACQUIRED MENINGOCOCCAL DISEASE . . . . . . . . . . . . . . . . 51 USE OF ECONOMIC EVALUATION FOR SETTING HEALTH POLICY . . . . . . . 55 PUBLIC COMMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58 ATTACHMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59